Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
37 hedge funds and large institutions have $14.1M invested in Merrimack Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 12 closing their positions.
5% more call options, than puts
Call options by funds: $58K | Put options by funds: $55K
3.57% less ownership
Funds ownership: 51.87% → 48.3% (-3.6%)
23% less funds holding
Funds holding: 48 → 37 (-11)
36% less capital invested
Capital invested by funds: $22M → $14.1M (-$7.96M)
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.88K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$6.37K |
| 3 |
JP Morgan Chase
New York
|
+$2.14K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$474 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$228 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$337K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$189K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$160K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$133K |
| 5 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$124K |
MACK Hedge Fund Activity: Q1 2020 in Review
37 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2020, worth a combined $14.1M — down 36% from $22M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MACK and 2 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $6.88K. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), exiting entirely with an estimated $337K sold.
- 37 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2020, down from 48 in Q4 2019.
- Funds reported $14.1M of Merrimack Pharmaceuticals, Inc. stock for Q1 2020, down 36% quarter-over-quarter.
- 2 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2020 and 12 closed out, a net change of -10 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2020 was UBS Group, an estimated $6.88K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2020 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $337K sold.
Based on aggregated 13F filings for Q1 2020.